soul trial oral semaglutide cardiovascular outcomes nejm 2025 results and in Patients with Type 2 Diabetes Canadian Perspectives 2025 Whiteboard on

You may qualify if you have: History of heart attack (myocardial infarction) History of stroke or TIA (transient ischemic attack) Coronary artery disease (CAD) with stents or bypass surgery Peripheral artery disease (PAD) Plus: BMI 27 kg/m If you have these conditions, ask your cardiologist about prescribing Wegovy for cardiovascular risk reductionthis may qualify for Medicare coverage

This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product

With insurance, the cost of tirzepatide treatments may be as low as $0 plus copay

Research models with chronic metabolic dysfunction often show NNMT overexpression that outpaces NAD+ synthesis capacity, creating a ceiling on how much metabolic improvement MOTS-c alone can produce